Background: Controversy surrounds the optimal composition, dosage, and duration of therapies for eradication of Helicobacter pylori. We prospectively compared omeprazole-based dual and triple therapies in the eradication of H. pylori in a randomized manner. Methods: Between June 1995 and March 1997, 1000 consecutive patients with acid-peptic disease associated with H. pylori infection (duodenal ulcer, 388 patients, gastric ulcer, 179 patients; duodenitis, 173 patients; gastritis, 260 patients) were prospectively recruited. They were randomized to either a 2-wk (OA) course of omeprazole 20 mg and amoxicillin 1 g, both given twice daily, or treatment for 1 wk (OCM) with omeprazole 20 mg once daily, clarithromycin 500 mg twice daily, and metronidazole 400 mg twice daily. Results: The age of these 1000 patients ranged from 16 to 90 yr, with a mean of 54.9 yr. Side effects occurred in 29.6% (95% confidence interval [CI] 25.6 -33.8%) and 10.6% (95% CI 8.0 -13.6%) of patients taking OCM and OA, respectively (p < 0.0001). Apart from taste disturbance, however, there were no significant differences in the incidences of side effects between the two groups. One patient in the OA group and four patients of the OCM group could not tolerate the medications, and therefore did not complete treatment (p ‫؍‬ 0.37). Seven and 13 patients in the OA and OCM groups, respectively, refused a second endoscopy (p ‫؍‬ 0.25). The remaining 975 patients underwent a second endoscopy. Positive endoscopic findings were significantly more common in the OA group (51/492; 10.4%; 95% CI 7.8 -13.4%) than in the OCM group (25/483; 5.2%; 95% CI 3.4 -7.5%) in the per-protocol (PP) analysis (p ‫؍‬ 0.004). On intent-to-treat (ITT) analysis, the overall eradication rates in the OA and OCM groups were 73.6% (95% CI 69.5-77.4%) and 92% (95% CI 89.3-94.2%), respectively (p < 0.0001). On PP analysis, the corresponding rates were 74.8% (95% CI 70.7-78.6%) and 95.2% (95% CI 92.9 -97.0%), respectively (p < 0.0001). Conclusions: A course of omeprazole, clarithromycin, and metronidazole for 1 wk is a safe, well-tolerated, efficacious, and cost-effective treatment for H. pylori infection. (Am J Gastroenterol 1998;93: 1436 -1442.
INTRODUCTION
Helicobacter pylori is currently well recognized as a major cause of peptic ulcer disease. The National Institutes of Health Consensus Development Conference has recommended the addition of antimicrobial agents to antisecretory drugs to treat all patients with H. pylori-associated peptic ulcer disease (1) . The development of effective therapies for the eradication of H. pylori has been difficult. Borody and colleagues (2) first described the classic triple therapy, which consisted of bismuth, metronidazole, and tetracycline. Despite achieving an eradication rate of approximately 90% in metaanalysis (3), its success has been hindered by poor patient compliance, attributed to complex dosing schedules as well as the large number of tablets to be taken per day. In addition, significant side effects are seen in about 30% of patients (4) . In response to the problems of bismuth-based regimens, attention has focused in recent years on various combinations of a proton-pump inhibitor with one or more antimicrobial agents (5) . Nevertheless, optimal treatment has not yet been established. A recent survey in five general practices in Scotland revealed that 56 different regimens were used for H. pylori eradication, the most common combination of drugs prescribed being omeprazole plus amoxicillin (6) . It is, therefore, timely that a standard, safe, effective, and cheap regimen be adopted for H. pylori eradication.
A 2-wk course of omeprazole-based dual therapy with either amoxicillin or clarithromycin has been a common alternative to the classic triple therapy, but the efficacy of these regimens varies considerably in different reports (7) . Good results have recently been obtained by using 1-wk triple therapy regimens containing a proton-pump inhibitor, clarithromycin, and either amoxicillin or a nitroimidazole (metronidazole or tinidazole) (8) . Most of these studies were, however, either not randomized, or randomized but small or multicenter trials (9 -14) . The present prospective randomized single-center trial comparing omeprazole-based dual and triple therapies in the eradication of H. pylori gives a new dimension to appropriate evaluation of these regimens.
PATIENTS AND METHODS
All patients diagnosed as having acid-peptic disease by the Division of Upper Gastrointestinal Surgery of the Department of Surgery, The University of Hong Kong at Queen Mary Hospital were eligible for the study. Patients were excluded if they were younger than 16 yr, had previous eradication therapy for H. pylori, had received bismuth compounds previously, were taking nonsteroidal antiinflammatory drugs or a proton-pump inhibitor, were diagnosed to have gastric carcinoma or lymphoma, had known or suspected allergy to the study drugs, had liver or renal impairment, or were pregnant or lactating. Patients who had taken H 2 -receptor antagonists, or whose ulcers had recently bled, were not excluded. A diagnosis of acid-peptic disease was made on endoscopy. All patients were fasted for at least 8 h before endoscopic examination under local pharyngeal anesthesia (Cetacaine Spray, Cetylite Industries, Pennsauken, NJ). An ulcer was defined as a mucosal defect of Ն 5 mm in at least one direction. Any mucosal defect of Ͻ 5 mm was classified as erosion. Gastritis was defined as the appearance of mucosal erosions or focal hemorrhagic lesions. Duodenitis was defined as the presence of nodularities, erosions, or inflamed mucosa in the first part of duodenum (15, 16) . Three antral mucosal biopsy specimens were taken and removed from the biopsy forceps (Olympus FB 25K, Olympus, Japan) with a needle. Two biopsy specimens were fixed with 10% formalin for histological examination, while one biopsy specimen was subjected to the rapid urease test (17) . Patients were considered to be positive for H. pylori if both histological examination and rapid urease test were positive. Patients with actively bleeding ulceration were treated at the same endoscopic examination with a combination of epinephrine injection or heater probe coagulation (Olympus HPU, Olympus, Japan). Cimetidine 400 mg was given orally twice daily before H. pylori infection was confirmed.
Patients were entered into the study if they did not meet any of the exclusion criteria, had positive findings on endoscopy (including ulcers, duodenitis, and gastritis), and were positive for H. pylori. Between June 1995 and March 1997, 1000 consecutive patients were prospectively recruited. Informed consent was obtained before randomization. They were randomized to either a 2-wk (OA) course of omeprazole 20 mg and amoxicillin 1 g both given twice daily, or a 1-wk (OCM) course of omeprazole 20 mg once daily, clarithromycin 500 mg twice daily, and metronidazole 400 mg twice daily.
The importance of compliance with antimicrobial treatment was stressed to the patients. They were advised of the possible side effects and were asked to take all the tablets prescribed to cure the disease. Regular follow-up at the outpatient clinic was arranged. They were asked to return to the clinic immediately after treatment if side effects developed. Otherwise, they were seen every month for the first 3 months and every 2-3 months thereafter. Any side effects as a result of treatment or persistence of symptoms after treatment were recorded by direct questioning at the time of follow-up. Compliance to treatment was ascertained by recall, being defined as an intake of Ͼ 90% of the tablets prescribed. This level of compliance was selected for ease of calculation as well as for critical assessment of the two regimens. Based on this level, an omission of more than one of the 14 doses of OCM or two of the 28 doses of OA would be classified as noncompliance. A second endoscopy was arranged for each patient 6 -8 wk after treatment and antral mucosal biopsy specimens were obtained once again. Eradication of H. pylori was considered successful if at the second endoscopy both rapid urease test and histology were negative for H. pylori. Eradication therapy was considered to be unsuccessful if either one or both of the two tests were positive for H. pylori.
All continuous values were expressed as mean Ϯ S.E. of the mean unless otherwise stated. Univariate analysis was performed by Student's t test for continuous variables and by 2 test (with Yates' correction where appropriate) for categorical variables. Fisher's exact test was used if any expected cell value in a 2-ϫ-2 table was Ͻ 5. All patients were evaluated in an intent-to-treat (ITT) analysis, in which patients without final H. pylori determination or with protocol violations were considered treatment failures. In contrast, for the per-protocol (PP) analysis, patients whose final H. pylori status was unknown, and those who were withdrawn either because of side effects or protocol violations were excluded. An exact binomial 95% confidence interval (CI) was calculated when appropriate. Data analyses were performed with a standard biomedical software package and differences with a p value of Ͻ 0.05 were regarded as statistically significant.
RESULTS
There was a preponderance of male patients (M:F ϭ 1.79:1). Age ranged from 16 to 90 yr with a mean of 54.9 yr. Most patients (72.7%) presented with pain or dyspepsia, whereas 273 patients (27.3%) presented with bleeding. The mean duration of pain or dyspepsia was 22.8 Ϯ 1.5 months. Forty-three patients had a past history of perforated duodenal ulcer treated with omental patch repair (39 patients) or truncal vagotomy and pyloroplasty (four patients). Cimetidine 400 mg twice daily was prescribed to 119 patients for a mean duration of 3.6 Ϯ 0.2 days before eradication therapy.
After randomization the two groups were well matched AJG -September 1998 OMEPRAZOLE-BASED DUAL AND TRIPLE THERAPYwith regard to age, gender, smoking habit, presentation, duration of complaint, concomitant medical problems, history of duodenal ulcer perforation, history of surgery, and prescription of cimetidine (Table 1) . Patients in the OCM group were older but the difference was not significant (p ϭ 0.07). There were significantly more patients with diabetes mellitus in the OCM group (p ϭ 0.01). The two groups were also well matched with regard to the diagnosis of duodenal ulcer, gastric ulcer, duodenitis, or, gastritis ( Table 2 ). All patients with actively bleeding ulcer were successfully managed by endoscopic intervention without rebleeding or morbidity.
Smokers were predominantly men and were older than nonsmokers (Table 3) . A history of bleeding in patients with duodenal or gastric ulcer was not associated with smoking habit. Ulcers, rather than gastritis or duodenitis, were more commonly found in smokers than in nonsmokers (p Ͻ 0.04).
Side effects occurred in 29.6% (95% CI 25.6 -33.8%) and 10.6% (95% CI 8.0 -13.6%) of patients taking OCM and OA, respectively (p Ͻ 0.0001) ( Table 4) . Apart from taste disturbance, however, there were no significant differences in the frequency of side effects between the two groups. Pseudomembranous colitis was not seen in either group and side effects were, in most instances, well tolerated by patients. One patient in the OA group and four patients in the OCM group could not tolerate the medications, and therefore did not complete the treatment (p ϭ 0.37) ( Table 4) . Seven and 13 patients in the OA and OCM groups, respectively, refused a second endoscopy (p ϭ 0.25). The remaining 975 patients underwent a second endoscopy after finishing their prescribed treatment (Table 5 ). Positive endoscopic findings were significantly more common in the OA group (51/492; 10.4%; 95% CI 7.8 -13.4%) than in the OCM group (25/ 483; 5.2%; 95% CI 3.4 -7.5%) in the PP analysis (p ϭ 0.004). The difference was also significant in the ITT analysis (10.2% vs 5.0%) (p ϭ 0.003).
There was good agreement between the rapid urease test and histology results after treatment. In the OA group, both tests were negative and positive in 368 and 108 patients, respectively. Either one of the two tests was positive in 16 1438 CHU et al. AJG -Vol. 93, No. 9, 1998 patients (urease alone in one patient; histology alone in 15 patients). In the OCM group, both tests were negative and positive in 460 and 19 patients, respectively. Histology alone was positive in four patients. The overall eradication rate in the OCM group was significantly better than in the OA group in either the ITT or PP analysis (Table 6 ). For the different diagnostic categories of duodenal ulcer, gastric ulcer, duodenitis, and gastritis, a significantly superior eradication rate in the OCM group, when compared with the OA group, was also evident (Table 6 ).
In those patients with a history of bleeding from their ulcers (Table 7) , at a median follow-up of 25.8 months, recurrent duodenal and gastric ulcer bleeding developed in one (0.6%; 95% CI 0 -3.4%) and two patients (3.1%, 95% CI 0.4 -10.8%), respectively.
On analysis of various other factors that might affect the success of eradication of H. pylori in these 1000 patients, female gender and nonsmoker status were associated with higher chance of a successful outcome on univariate analysis (Table 8) . On multivariate logistic regression analysis, eradication by OCM and nonsmoker status were independent predictors of success in eradication. Nonsmoker status, however, was not a significant factor affecting success of eradication by OCM (p ϭ 0.26) ( Table 8) .
DISCUSSION
Cure of H. pylori infection leads to long-term remission from peptic ulcer disease (18, 19) . The organism, however, is well adapted to the habitat of its host and currently no medical therapy is 100% effective. Over the past decade, many combinations of medication have been studied but the optimal regimen remains unsettled. The "standard" bismuth-based triple therapy is associated with problems including poor compliance, frequent side effects, and significant reduction in efficacy for metronidazole-resistant strains of H. pylori (20) . To improve patient compliance and to reduce the frequency of side effects, various regimens based on proton-pump inhibitors such as omeprazole have been developed. Advantages of omeprazole include faster healing of ulcer and relief of symptoms than H 2 -receptor antagonists, improvement of minimum inhibitory concentration values of some antibiotics, and its in vitro antimicrobial activity against H. pylori (21). Monotherapy with omeprazole suppresses but does not eradicate H. pylori (22) . Dual therapy with omeprazole and amoxicillin (OA) for 2 wk is a well-tolerated and simple alternative to bismuthbased triple therapy. Although eradication rates in excess of 80% have been reported using OA, its efficacy is highly variable and unpredictable (23, 24) . Such marked variability in results is not noted in dual therapy with omeprazole and clarithromycin (OC) for 2 wk (25) . Nevertheless, the overall efficacy of OC is only 71% and the regimen is relatively expensive in its usual dosage (25, 26) . In recent years, higher rates of H. pylori eradication have been achieved using 1 wk triple-therapy regimens containing a protonpump inhibitor and two antimicrobial agents (8) . Unfortunately, most of these studies were either not randomized, or randomized but small or multicenter trials (9 -14, 27, 28) . To our knowledge, the present study is currently the largest single-center prospective randomized trial evaluating the use of omeprazole-based dual and triple therapy in the eradication of H. pylori. A single-center study in a very small geographical location such as Hong Kong may obviate problems with different strains of H. pylori, which may otherwise be present in different populations and may make the interpretation of results difficult.
Because the eradication of H. pylori is an objective end point, the present study was not blinded. We have confirmed a superior rate of eradication of H. pylori by a 1-wk course of OCM in comparison to a 2-wk course of OA. The eradication rate of Ͼ 90% achieved by OCM was consistent with most recent studies (5, 29) . A shorter, 1-wk course of triple therapy is adequate to attain an eradication rate of Ͼ 90% (29) . Recent intake of proton-pump inhibitor may shift the distribution of the bacteria to the corpus of stomach (30) . Thus, antral biopsies alone may overestimate the eradication of H. pylori. During the design of the present study in early 1995, we tried to mitigate this potential overestimation by performing follow-up biopsies 6 -8 wk after treatment. The recent guidelines for clinical trials from the Working Party of the European Helicobacter pylori Study Group recommended inclusion of corpus biopsies in the detection of H. pylori after eradication therapy (31) .
There appears to be no benefit in increasing the dose of omeprazole from 20 mg daily to 40 mg daily in omeprazolebased triple therapy (12) . Moreover, the use of omeprazole 20 mg daily rather than 40 mg daily brings the cost of the regimen down. In contrast to amoxicillin, the activity of metronidazole is relatively independent of pH (32, 33) . Consequently, metronidazole is used in the present study in view of a lower dose of omeprazole. On the other hand, the choice of proton-pump inhibitor appears unimportant, with similar results being reported for lansoprazole-(at 30 mg once or twice daily) or pantoprazole-(at 40 mg twice daily) based triple therapies (34, 35) . Therefore, the impressive eradication rate achieved with OCM may be the result of a AJG -September 1998 OMEPRAZOLE-BASED DUAL AND TRIPLE THERAPYsynergistic interaction between clarithromycin, metronidazole, and one of the proton-pump inhibitors.
We have included patients whose ulcers have recently bled because a number of recent studies have confirmed the value of H. pylori eradication for ulcer healing, as well as obviating rebleeding in such patients (36 -40) . The overall ulcer healing rate was significantly higher in patients taking OCM rather than OA in the present study. The choice of eradication regimen in a patient whose ulcer has recently bled is especially important because a less-effective regimen may expose the patient to an unnecessary risk of rebleeding.
Although side effects were significantly more common with the use of OCM (29.6%) than with OA (10.6%), such side effects were well tolerated by patients and noncompliance occurred in Ͻ 1% of patients taking OCM. The high compliance rate observed in the OCM group could also be attributed to the short duration of treatment, the simple dosing schedules, and the pretreatment education of patients. The most frequent side effect in the OCM group was taste disturbance, which was known to be associated with the use of clarithromycin (26) .
On multivariate logistic regression analysis, apart from treatment with OCM, smoking was also found to be an independent risk factor predicting failure of eradication. Evaluation of the 500 patients randomized to OCM showed that smoking was not a significant factor predicting failure of eradication. In accordance with other published studies, smoking adversely affects the success of eradication by OA (41, 42) . It appeared, therefore, that OCM therapy is a much better choice than OA for smokers.
The prevalence of metronidazole-resistant strains of H. pylori has been considered to be a major factor determining the success of eradication by metronidazole-containing regimens, especially for bismuth-based therapies (43, 44) . In addition, routine metronidazole susceptibility testing before starting a metronidazole-containing regimen is advocated (43) . Culture, however, takes time and adds costs to the management of these patients. In a community setting, metronidazole susceptibility testing may not be readily available. A recent study from Hong Kong revealed that the overall metronidazole resistance rate was 53.5% in local patients with peptic ulcer disease (45) . Despite frequent resistance to metronidazole, the metronidazole-containing OCM attained overall eradication rates of 92% and 95.2% in the present study on ITT and PP analyses, respectively. Indeed, a recent study has demonstrated that the efficacy of a 10-day course of omeprazole 20 mg, clarithromycin 250 mg, and metronidazole 400 mg, all given twice daily, was independent of in vitro metronidazole susceptibility (46) . Nevertheless, the eradication rate in patients who received a 10-day course of omeprazole 20 mg, amoxicillin 750 mg, and metronidazole 400 mg, all given twice daily, was significantly reduced in patients with metronidazole-resistant strains of H. pylori (46) . The observation that the efficacy of OCM was not affected by metronidazole resistance helps to 
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CHU et al. AJG -Vol. 93, No. 9, 1998 explain why the reported efficacy of OCM appears remarkably similar in various countries with different prevalences of metronidazole-resistant strains of H. pylori (5, 13) . In a recent metaanalysis, the efficacy of a combination of omeprazole, clarithromycin, and metronidazole was superior to that of omeprazole, amoxicillin, and metronidazole (25) . This finding was similar to that of the multicenter MACH I study (13) . The reason why metronidazole resistance apparently does not affect the efficacy of OCM is currently unknown.
Using decision tree models to compare various management strategies, it has been demonstrated that eradication therapy for H. pylori provided the most cost-effective management for ulcer disease (47, 48) . The cost of OCM at Queen Mary Hospital is about US $37.00 per course, whereas that for OA is approximately US $45.00 per course at the time of writing. In view of the lower cost and higher efficacy of OCM, it is undoubtedly more cost-effective than OA for the eradication of H. pylori.
The Department of Surgery at Queen Mary Hospital is a public facility where individuals of different classes of the population have access to its services. The Division of Upper Gastrointestinal Surgery also runs two specialist outpatient clinics with public access. Patients in the present study included emergency admissions to the hospital or attendees to the outpatient clinic of the Division. The results of the present study could, therefore, be extrapolated to the general public.
In conclusion, a 1-wk course of omeprazole, clarithromycin, and metronidazole is a safe, well-tolerated, efficacious, and cost-effective treatment for H. pylori infection. 
